Skip to content

Psychedelic-assisted therapy research published in 2023

Page 2 of 7: studies 21 to 40 of 140, newest first. Back to the psychedelic-assisted therapy overview

Studies

Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis

JMIR Formative Research November 28, 2023 George Danias, Jacob Appel 13 citations

Background Psychedelic substances have demonstrated promise in the treatment of depression, anxiety, and substance use disorders. Significant media coverage has been dedicated to psychedelic medicine, but it is unclear whether the public associates psilocybin with its potential therapeutic benefits. The COVID-19 pandemic led to an increase in depression, anxiety, and substance abuse in the...

DOI: 10.2196/43850 (opens in new tab) Anxiety Depression Google trends Antidepressant +9

Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials

Journal of Psychedelic Studies November 20, 2023 Tahlia R. Harrison 23 citations

Abstract Background and aims Psychedelic-assisted therapy (P-AT) has been shown to reduce post-traumatic stress disorder (PTSD), depression, and anxiety symptoms, and is likely to be approved in the United States (US) in the coming years. However, concerns about participant safety in these early trials have surfaced, including allegations of sexual misconduct. This paper aims to illuminate how...

DOI: 10.1556/2054.2023.00267 (opens in new tab) Full text (opens in new tab) Anxiety Clinical trial Informed consent Inclusion mineral +5

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Psychiatry Research November 1, 2023 Sipan Haikazian, David C J Chen-Li, Danica E. Johnson et al. 121 citations

The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. Data was pooled using a random-effects model. The primary outcome...

Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’

Deleuze and Guattari Studies October 27, 2023 Patricia Kubala 6 citations

This paper argues that practitioners of psychedelic-assisted therapy could learn a great deal from Deleuze and Guattari’s critique of psychoanalysis in Anti-Oedipus, as well as the practice of materialist psychiatry – schizoanalysis – that they offer in its stead. Much of the clinical research on psychedelics (particularly psilocybin) over the past fifteen years has privileged mystical...

Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences

Religions October 19, 2023 Brian Claude Macallan 3 citations

This paper explores Christian responses to religious and spiritual experiences (RSEs) associated with psilocybin-assisted therapy (PAT). It addresses the challenges of defining and understanding spiritual and religious experiences and examines the theological implications of PAT-induced RSEs. It highlights the growing acceptance of PAT as a therapeutic approach and its potential benefits for...

DOI: 10.3390/rel14101312 (opens in new tab) Psychedelic therapy Religious experience Christian responses Psilocybin therapy: psilocybin +16

Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists

Frontiers in Psychology October 12, 2023 Jakub Greń, Filip Tylš, Michał Lasocik et al. 21 citations

The growing interest in and prevalence of the use of psychedelics, as well as the potential benefits and negative consequences associated with psychedelic experiences, create a need for mental health specialists to be able to provide adequate and effective intervention regarding the content and consequences of these experiences, that is, psychedelic integration. At the same time, current...

Psychedelic Therapy: Beyond Brain, Embracing Culture

October 4, 2023 Inês Hipólito, Sofia Tzima 2 citations preprint

This paper argues that cultural embodiment plays a pivotal factor in shaping psychological experiences, influencing both the development and treatment of mental health conditions. Traditional analytic philosophy of mind proposes that the efficacy of psychedelic-assisted therapy should be understood as a brain computational model update. Beyond the scientific understanding of neural activity, we...

DOI: 10.31234/osf.io/rjngs (opens in new tab) Situated Narrative Perspective graphical Psychological intervention +2

Assessing potential of psilocybin for depressive disorders

Expert Opinion on Investigational Drugs October 3, 2023 Zofia Kozak, Matthew W Johnson, Scott T Aaronson 10 citations

There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.

Potential use of psilocybin drugs in the treatment of depression

Expert Opinion on Emerging Drugs October 2, 2023 Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek et al. 4 citations

Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to...

Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.

Journal of Palliative Medicine October 1, 2023 Noah D Gold, Austin J. Mallard, Jacob C Hermann et al. 5 citations

Background: Amyotrophic lateral sclerosis (ALS) is an aggressive, terminal neurodegenerative disease that causes death of motor neurons and has an average survival time of 3-4 years. ALS is the most common motor neuron degenerative disease and is increasing in prevalence. There is a pressing need for more effective ALS treatments as available pharmacotherapies do not reverse disease progression...

Moving beyond a figurative psychedelic literacy: Metaphors of psychiatric symptoms in ayahuasca narratives.

Social Science & Medicine October 1, 2023 Alex K. Gearin 6 citations

Metaphors, analogies, and similes commonly appear in narratives of drinking the potent psychedelic "ayahuasca", presenting an intriguing transcultural pattern. Based upon survey and field research at an ayahuasca healing center in Pucallpa, Peru, the article investigates conceptual metaphors in narratives of ayahuasca experiences made by the visiting international guests. Bodily metaphors and...

Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.

Current Psychiatry Reports October 1, 2023 Aaron Wolfgang, Charles W Hoge 15 citations

This review discusses the current and projected landscape of psychedelic-assisted therapy (PAT), with a focus on clinical, legal, and implementation considerations in Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. 3,4-Methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted therapy have shown promising outcomes in efficacy, safety, tolerability, and...

How psychedelic-assisted therapy works for depression: expert views and practical implications from an exploratory Delphi study.

Frontiers in Psychiatry September 28, 2023 Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al. 5 citations

As investigations into the efficacy of psychedelic-assisted psychotherapy to treat depression continue, there is a need to study the possible mechanisms of action that may contribute to the treatment's antidepressant effects. Through a two-round Delphi design, the current study investigated experts' opinions on the psychological mechanisms of action associated with the antidepressant effects of...

DOI: 10.3389/fpsyt.2023.1265910 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Depression research Therapeutic mechanisms +1

Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient

Frontiers in Psychiatry September 20, 2023 Taylor Black 2 citations

Psychedelic-assisted treatment (PAT) for mental health is in renaissance. Psilocybin and MDMA stand near FDA approval, and US cities and states are decriminalizing or regulating the non-clinical use of psilocybin. However, neither FDA indications nor a regulated use model sufficiently address the complex needs and opportunities for an improved treatment of addiction. When paired with disability...

DOI: 10.3389/fpsyt.2023.1159843 (opens in new tab) Addiction Population Mental illness Legalization +6

Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program

Journal of Psychoactive Drugs September 18, 2023 Emmy Manson, Erin Ryding, Wes Taylor et al. 13 citations

Novel and traditional psychedelic medicines are attracting interest as potential treatments of mental illness. Before psychedelic therapies can be made available in culturally safe and effective ways to diverse peoples, the field must grapple with the complex legacies of colonialism and ongoing clashes between biomedical and Indigenous Ways of Knowing. This article presents results of a pilot...

DOI: 10.1080/02791072.2023.2258120 (opens in new tab) Indigenous Thematic analysis Experiential learning Gratitude +7

Psilocybin for anorexia nervosa: If it helps, let's learn how.

Med September 8, 2023 Evelyn Attia, Joanna E Steinglass 7 citations

Existing treatments for adults with anorexia nervosa (AN) have limited effectiveness. AN is a brain-based disorder with behavioral and cognitive features leading to severe undernourishment. Peck et al. conducted a small open trial suggesting safety and tolerability of psilocybin for AN,1 opening an avenue for further investigation into the neural mechanisms involved.

DOI: 10.1016/j.medj.2023.08.003 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Eating disorders Mental health treatment Psilocybin research +1

Psychedelic-assisted psychotherapy: hope and dilemma

The Lancet Regional Health - Europe September 1, 2023 The Lancet Regional Health – Europe 10 citations

Psychedelic-assisted psychotherapy: hope and dilemmaPsychedelic-assisted psychotherapy is an emerging therapeutic approach that combines the use of psychedelics (a subclass of hallucinogenic drugs) and psychotherapy for the treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.Compared with current treatments for depression, psychedelic-assisted psychotherapy has...

DOI: 10.1016/j.lanepe.2023.100727 (opens in new tab) Dilemma Psychotherapist Psychoanalysis Epistemology

Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies

Mindfulness September 1, 2023 Richard Chambers, Devon Stoliker, Otto Simonsson 10 citations

Abstract Objectives The mindfulness-informed intervention that has so far received the most attention as an adjunct to psychedelic-assisted psychotherapy is Acceptance and Commitment Therapy (ACT), but little remains known about potential synergies between psychedelic-assisted psychotherapy and mindfulness-based interventions such as Mindfulness-Based Cognitive Therapy (MBCT). This paper...

DOI: 10.1007/s12671-023-02206-4 (opens in new tab) Full text (opens in new tab) Meditation Psychotherapist Mindfulness-based cognitive therapy Cognition +4